Home › Research › Costs and economics
The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in Sweden
Xia X, Aye S, Frisell O, Aho E, Handels R, Li Y, Wimo A, Winblad B, Eriksdotter M, Skillbäck TB, Kern S, Zetterberg H, et al.. PharmacoEconomics, 2025-07-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction We sought to estimate the cost-effective price for lecanemab for treating early Alzheimer's disease in Sweden from the perspective of formal care payers. Methods We developed a Markov model with states defined by disease severity and care setting. The model was populated by integrated clinical and economic data from Swedish registers. We included patients with biomarker-confirmed Alzheimer's disease and fitted survival models for transitions between model states. Costs in 2023 Swedish kronor (SEK), life-years (LYs), and quality-adjusted LYs (QALYs) over a 10-year time horizon were estimated for standard of care and for lecanemab in addition to standard of care, assuming a maximum treatment duration of 3 years with lecanemab and no treatment effect after treatment stops. We also explored the impact of different assumptions regarding treatment efficacy and duration. Results Treatment with lecanemab over 3 years resulted in 0.13 LYs gained, 0.17 QALYs gained, and a net cost increase of 87,146 SEK (€1 = 11.5 SEK, $US1 = 10.6 SEK) due to administration and monitoring, before considering the cost of drug. The cost-effective price of lecanemab at a willingness-to-pay level of 1 million SEK per QALY was 33,886 SEK per year of treatment. The health gain, net costs, and cost-effective price of lecanemab varied significantly by treatment duration, potential residual effects, and patient characteristics. Conclusions The future price of lecanemab in European countries is unknown. However, treatment with lecanemab is unlikely to be cost effective in Sweden at the levels of current list prices in the USA.
What this study adds
Evidence grade: Moderate
In a Swedish Markov model, three years of lecanemab for early Alzheimer's disease resulted in 0.13 life-years gained, 0.17 QALYs gained, and a net cost increase of 87,146 SEK before considering the cost of the drug. Reported effect size: 0.17 QALYs gained; cost-effective price 33,886 SEK per treatment year at 1 million SEK/QALY.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Xia, X., Aye, S., Frisell, O., Aho, E., Handels, R., Li, Y., et al. (2025). The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in Sweden. PharmacoEconomics. https://doi.org/10.1007/s40273-025-01527-7
Vancouver
Xia X, Aye S, Frisell O, Aho E, Handels R, Li Y, et al. The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in Sweden. PharmacoEconomics. 2025. doi:10.1007/s40273-025-01527-7. PMID: 40730714.
BibTeX
@article{xia2025-40730714,
author = {Xia, X. and Aye, S. and Frisell, O. and Aho, E. and Handels, R. and Li, Y. and Wimo, A. and Winblad, B. and Eriksdotter, M. and Skillbäck, T. B. and Kern, S. and Zetterberg, H. and others},
title = {{The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in Sweden}},
journal = {PharmacoEconomics},
year = {2025},
doi = {10.1007/s40273-025-01527-7},
pmid = {40730714},
url = {https://doi.org/10.1007/s40273-025-01527-7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Treatment with lecanemab over 3 years resulted in 0.13 LYs gained, 0.17 QALYs gained, and a net cost increase of 87,146 SEK (€1 = 11.5 SEK, $US1 = 10.6 SEK) due to administration and monitoring, before considering the cost of drug.
- The health gain, net costs, and cost-effective price of lecanemab varied significantly by treatment duration, potential residual effects, and patient characteristics.
Why it matters
In a Swedish Markov model, three years of lecanemab for early Alzheimer's disease resulted in 0.13 life-years gained, 0.17 QALYs gained, and a net cost increase of 87,146 SEK before considering the cost of the drug. The cost-effective price at a willingness-to-pay level of 1 million SEK per QALY was 33,886 SEK per year of treatment, and the health gain, net costs, and cost-effective price varied significantly by treatment duration, potential residual effects, and patient characteristics.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designmodelling
- Effect size0.17 QALYs gained; cost-effective price 33,886 SEK per treatment year at 1 million SEK/QALY
- Evidence strengthModerate
Limitations
Transitions from MCI to mild dementia and death were modelled from the US NACC database rather than Swedish patients; APOE genotype could not be accounted for; productivity losses and informal care costs were excluded; utility inputs came from heterogeneous quality-of-life studies; and the trial hazard ratio for CDR-global progression was used as a proxy for effect on disease progression.
How this study scored 48/100
Published in a peer-reviewed journal, and it is a computer model rather than new measurements. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 47 of the 98 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (PharmacoEconomics) |
| Journal's citation record | 2 / 4 | PharmacoEconomics: journal h-index 153 (OpenAlex, 2026-10-29) |
| Study design | 3 / 12 | A computer model rather than new measurements |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Linus Jönsson: h-index 55 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40730714) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 47 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 47 of the 98 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Costs and economics from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.